The Food and Drug Administration approved NephroGenex Inc.'s (Nasdaq: NRX) Investigational New Drug application for clinical studies with intravenous Pyridorin to treat acute kidney injury sending the stock price soaring 86 cent to $2.30.
FDA approves NephroGenex's IND application
December 14, 2015 at 13:06 PM EST
